Market Research Report
Investigation Report on China's Trastuzumab Market 2021-2025
|Published by||China Research and Intelligence||Product code||1002612|
|Published||Content info||50 Pages
Delivery time: 1-2 business days
|Investigation Report on China's Trastuzumab Market 2021-2025|
|Published: April 23, 2021||Content info: 50 Pages||
Trastuzumab is a monoclonal antibody used to treat breast cancer and stomach cancer, and is especially used for the treatment of certain HER-2 positive cancers. The original drug, HERCEPTIN was developed by Roche's subsidiary corporation. In 2002, Trastuzumab entered the Chinese market. Currently, besides Roche, the other main manufacturer in the Chinese market is Shanghai Henlius Biotech, Inc.
According to CRI's market research, the sales revenue of Trastuzumab in the Chinese market has an accelerated increase from 2016 to 2019. In 2020, the sales value of Trastuzumab in China was approximately CNY1.52 billion, which decreased 22.5% YoY. The CAGR of sales value of Trastuzumab in China is about 19.8% in 2016 to 2020. CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Trastuzumab will have a recovery growth from 2021 to 2025.
CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Trastuzumab will have a recovery growth from 2021 to 2025. In addition, the sales of Trastuzumab will also increase due to the price reduction and market expansion. Since Trastuzumab entered the Chinese market, its price has had a decreasing trend. For example, Roche's HERCEPTIN's price has dropped from CNY24,500 to CNY5,500. CRI predicts that with the launch of biosimilar drugs, the price of Trastuzumab may keep falling, which will lead to an increase in sales. Moreover, as the detection of HER-2 for gastric cancer continues to be promoted, Trastuzumab will have larger market penetration in the treatment of gastric cancer in the future.